Insmed to Present at the Cowen and Company 37th Annual Health Care Conference
February 28 2017 - 8:00AM
Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical
company focused on the unmet needs of patients with rare diseases,
announced today that Will Lewis, president and chief executive
officer of Insmed, will present at the Cowen and Company 37th
Annual Health Care Conference in Boston, MA on Tuesday, March 7,
2017 at 11:20 a.m. ET.
Mr. Lewis’ presentation will be webcast live and can be accessed
by visiting the investor relations section of the company’s website
at www.insmed.com. The webcast will be archived for a period of 90
days following the conclusion of the live event.
About Insmed
Insmed Incorporated is a global biopharmaceutical company
focused on the unmet needs of patients with rare diseases. The
company is advancing a global phase 3 clinical study of ARIKAYCE
(liposomal amikacin for inhalation) for adult patients with
treatment refractory nontuberculous mycobacteria (NTM) lung disease
caused by Mycobacterium avium complex (MAC), a rare and often
chronic infection that is capable of causing irreversible lung
damage and can be fatal. There are currently no approved inhaled
products specifically indicated for the treatment of refractory NTM
lung infections caused by MAC in the United States or European
Union (EU). Insmed's earlier-stage clinical pipeline includes
INS1007, a novel oral reversible inhibitor of DPP1 with therapeutic
potential in non-CF bronchiectasis, and INS1009, an inhaled
nanoparticle formulation of a treprostinil prodrug that may offer a
differentiated product profile for rare disorders, including
pulmonary arterial hypertension (PAH). For more information, visit
www.insmed.com.
Investor Contact:
Laura Perry or Heather Savelle
Argot Partners
212-600-1902
laura@argotpartners.com
heather@argotpartners.com
Insmed (NASDAQ:INSM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Insmed (NASDAQ:INSM)
Historical Stock Chart
From Sep 2023 to Sep 2024